Evidence map›Paper›PMID 37004712›Full record

ArticleThe Lancet. Child & adolescent health2023

Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial.

Eric M Thompson, Daniel Landi, Michael C Brown, Henry S Friedman, Roger McLendon, James E Herndon, Evan Buckley, Dani P Bolognesi, Eric Lipp, Kristin Schroeder and 10 more

Open access · greenAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in The Lancet. Child & adolescent health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 3 pooled it
12.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 3 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. The effect of oncolytic virotherapy on pediatric brain tumor- a systematic review.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2025
    Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Viral Microglia Reprogramming Clears Oligomeric Neurotoxic Debris.bioRxiv : the preprint server for biology · 2026
    Article
  7. Advancements in Drug Delivery Systems in Glioblastoma Therapy.International journal of molecular sciences · 2026
    Review
  8. Review
  9. Review
  10. Review
  11. Immunotherapy in central nervous system tumors.International journal of surgery (London, England) · 2025
    Review
  12. Review
  13. Polio virotherapy provokes MDA5 signaling and CD4Microbiology and molecular biology reviews : MMBR · 2025
    Review
  14. Review
  15. Review
  16. Article
  17. Convection enhanced delivery of Rhenium (Nature communications · 2025
    Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 1 country.

Eric M ThompsonDepartment of Neurological Surgery, Duke University, Durham, NC, USA; Preston Robert Tisch Brain Tumor Center, Duke University, Durham, NC, USA.
Daniel LandiPreston Robert Tisch Brain Tumor Center, Duke University, Durham, NC, USA; Department of Pediatrics, Duke University, Durham, NC, USA.
Michael C BrownDepartment of Neurological Surgery, Duke University, Durham, NC, USA; Preston Robert Tisch Brain Tumor Center, Duke University, Durham, NC, USA.
Henry S FriedmanDepartment of Neurological Surgery, Duke University, Durham, NC, USA; Preston Robert Tisch Brain Tumor Center, Duke University, Durham, NC, USA.
Roger McLendonPreston Robert Tisch Brain Tumor Center, Duke University, Durham, NC, USA; Department of Pathology, Duke University, Durham, NC, USA.
James E HerndonDepartment of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA; Duke Cancer Institute Biostatistics, Duke University, Durham, NC, USA.
Evan BuckleyDuke Cancer Institute Biostatistics, Duke University, Durham, NC, USA.
Dani P BolognesiDepartment of Surgery, Duke University, Durham, NC, USA.
Eric LippPreston Robert Tisch Brain Tumor Center, Duke University, Durham, NC, USA.
Kristin SchroederDepartment of Pediatrics, Duke University, Durham, NC, USA.
Oren J BecherDepartment of Pediatrics, Mount Sinai Health System, New York, NY, USA.
Allan H FriedmanDepartment of Neurological Surgery, Duke University, Durham, NC, USA; Preston Robert Tisch Brain Tumor Center, Duke University, Durham, NC, USA.
Zachary McKayDepartment of Neurological Surgery, Duke University, Durham, NC, USA.
Ashley WalterPreston Robert Tisch Brain Tumor Center, Duke University, Durham, NC, USA.
Stevie ThreattPreston Robert Tisch Brain Tumor Center, Duke University, Durham, NC, USA.
Denise JaggersPreston Robert Tisch Brain Tumor Center, Duke University, Durham, NC, USA.
Annick DesjardinsDepartment of Neurological Surgery, Duke University, Durham, NC, USA; Preston Robert Tisch Brain Tumor Center, Duke University, Durham, NC, USA.
Matthias GromeierDepartment of Neurological Surgery, Duke University, Durham, NC, USA; Preston Robert Tisch Brain Tumor Center, Duke University, Durham, NC, USA.
Darell D BignerDepartment of Neurological Surgery, Duke University, Durham, NC, USA; Preston Robert Tisch Brain Tumor Center, Duke University, Durham, NC, USA.
David M AshleyDepartment of Neurological Surgery, Duke University, Durham, NC, USA; Preston Robert Tisch Brain Tumor Center, Duke University, Durham, NC, USA. Electronic address: david.ashley@duke.edu.
Duke University · USMount Sinai Health System · USNeurological Surgery · US

Funding

Innate Antiviral Signals for Cancer ImmunotherapyR01NS108773 · NINDS · DUKE UNIVERSITY · PI Matthias Gromeier, Smita K. Nair · 2018 to 2026
$3.3M
Reviving cancer immune surveillance with CD4 T cell helpK99CA263021 · NCI · DUKE UNIVERSITY · PI BROWN, MICHAEL CLAVON · 2021 to 2021
$105k
NCI NIH HHS K99 CA263021NINDS NIH HHS R01 NS108773
6 · The paper itself

Abstract

backgroundOutcomes of recurrent paediatric high-grade glioma are poor, with a median overall survival of less than 6 months. Viral immunotherapy, such as the polio-rhinovirus chimera lerapolturev, is a novel approach for treatment of recurrent paediatric high-grade glioma and has shown promise in adults with recurrent glioblastoma. The poliovirus receptor CD155 is ubiquitously expressed in malignant paediatric brain tumours and is a treatment target in paediatric high-grade glioma. We aimed to assess the safety of lerapolturev when administered as a single dose intracerebrally by convection enhanced delivery in children and young people with recurrent WHO grade 3 or grade 4 glioma, and to assess overall survival in these patients.

methodsThis phase 1b trial was done at the Duke University Medical Center (Durham, NC, USA). Patients aged 4-21 years with recurrent high-grade malignant glioma (anaplastic astrocytoma, glioblastoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, or anaplastic pleomorphic xanthoastrocytoma) or anaplastic ependymoma, atypical teratoid rhabdoid tumour, or medulloblastoma with infusible disease were eligible for this study. A catheter was tunnelled beneath the scalp for a distance of at least 5 cm to aid in prevention of infection. The next day, lerapolturev at a dose of 5 × 10

findingsBetween Dec 5, 2017, and May 12, 2021, 12 patients (11 unique patients) were enrolled in the trial. Eight patients were treated with lerapolturev. The median patient age was 16·5 years (IQR 11·0-18·0), five (63%) of eight patients were male and three (38%) were female, and six (75%) of eight patients were White and two (25%) were Black or African American. The median number of previous chemotherapeutic regimens was 3·50 (IQR 1·25-5·00). Six of eight patients had 26 treatment-related adverse events attributable to lerapolturev. There were no irreversible (ie, persisted longer than 2 weeks) treatment-related grade 4 adverse events or deaths. Treatment-related grade 3 adverse events included headaches in two patients and seizure in one patient. Four patients received low-dose bevacizumab on-study for treatment-related peritumoural inflammation or oedema, diagnosed by both clinical symptoms plus fluid-attenuated inversion recovery MRI. The median overall survival was 4·1 months (95% CI 1·2-10·1). One patient remains alive after 22 months.

interpretationConvection enhanced delivery of lerapolturev is safe enough in the treatment of recurrent paediatric high-grade glioma to proceed to the next phase of trial.

fundingSolving Kids Cancer, B+ Foundation, Musella Foundation, and National Institutes of Health.

Indexed as

AstrocytomaBrain NeoplasmsCerebellar NeoplasmsGlioblastomaGliomaPoliomyelitisAdolescentAdultChildFemaleHumansImmunotherapyMaleNeoplasm Recurrence, LocalRhinovirus

Identifiers

PMID37004712
PMCPMC11104482
OpenAlexW4361245706

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.